Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

285.16USD
11:52am EST
Change (% chg)

$0.41 (+0.14%)
Prev Close
$284.75
Open
$284.28
Day's High
$286.35
Day's Low
$281.08
Volume
947,677
Avg. Vol
1,638,810
52-wk High
$333.65
52-wk Low
$223.02

Select another date:
Photo

Biogen to pay Forward Pharma $1.25 billion to protect MS drug

Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion to license the Danish company's patents covering multiple sclerosis drugs, providing Biogen an insurance policy on future sales of Tecfidera, its blockbuster oral treatment for the disease.

BRIEF-FORWARD PHARMA AGREES TO ENTER INTO SETTLEMENT AND LICENSE AGREEMENT WITH BIOGEN

* FORWARD PHARMA AGREES TO ENTER INTO SETTLEMENT AND LICENSE AGREEMENT WITH BIOGEN

UPDATE 1-Biogen to pay $1.25 bln in license fees to protect MS drug

Jan 17 Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to license the Danish company's patents covering multiple sclerosis drugs including Biogen's flagship drug, Tecfidera.

Biogen in $1.25 bln deal with Forward Pharma to protect MS drug

Jan 17 Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to gain access to the Danish company's intellectual property as it seeks to protect the patent life of its flagship multiple sclerosis drug, Tecfidera.

BRIEF-Biogen, Forward Pharma to enter into settlement and license agreement

* Biogen and Forward Pharma agree to enter into settlement and license agreement

BRIEF-Biogen spin-off Bioverativ commences when-issued trading of common stock

* Biogen spin-off Bioverativ commences when-issued trading of common stock

FDA approves Biogen drug for lead genetic cause of infant death

The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in infants.

Investors see Biogen CEO choice as friendly to potential takeover

NEW YORK The surprise selection of Michel Vounatsos to run Biogen Inc signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.

Biogen names top executive Vounatsos as CEO

Biogen Inc, the U.S. drug maker focused on neurological, autoimmune and rare diseases, said on Monday it had appointed its chief commercial officer, Michel Vounatsos, as chief executive officer, ending a five-month search.

Further promising data seen with Biogen Alzheimer's drug: study

Gradually increasing the dose of Biogen Inc's experimental Alzheimer's disease drug appeared to reduce the risk of brain swelling compared to higher fixed doses, interim 12-month results from a small study released on Thursday showed.

Select another date: